Breakthroughs in cancer biology have led to FDA-approved targeted therapies now standard in managing many malignancies. However, long-term, cancer-free survival remains a challenge, highlighting the need for further research on factors like drug-target engagement, a key to therapeutic success. In collaboration with Dr. Barroso's group at AMC, we have developed a fluorescence lifetime imaging technique to non-invasively quantify in vivo drug-target interactions in real time. Validated in a breast cancer model for drugs like Trastuzumab and Cetuximab, our robust imaging pipeline is advancing new molecular probes in partnership with domestic and international collaborators.

Lead PI: Dr. Xavier Intes